0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

      The New England journal of medicine

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.

          Related collections

          Author and article information

          Journal
          26412456
          10.1056/NEJMoa1507643

          Comments

          Comment on this article

          scite_